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Abstract 
A safe, effective, and inexpensive vaccine against typhoid and other Salmonella diseases is urgently needed. In order to address 
this need, we are developing a novel vaccine platform employing buoyant, self-adjuvanting gas vesicle nanoparticles (GVNPs) 
from the halophilic archaeon Halobacterium sp. NRC-1, bioengineered to display highly conserved Salmonella enterica antigens. 
As the initial antigen for testing, we selected SopB, a secreted inosine phosphate effector protein injected by pathogenic S. 
enterica bacteria during infection into the host cells. Two highly conserved sopB gene segments near the 3'- region, named sopB4 
and sopB5, were each fused to the gvpC gene, and resulting SopB-GVNPs were purified by centrifugally accelerated flotation. 
Display of SopB4 and SopB5 antigenic epitopes on GVNPs was established by Western blotting analysis using antisera raised 
against short synthetic peptides of SopB. Immunostimulatory activities of the SopB4 and B5 nanoparticles were tested by 
intraperitoneal administration of SopB-GVNPs to BALB/c mice which had been immunized with S. enterica serovar 
Typhimurium 14028 ΔpmrG-HM-D (DV-STM-07), a live attenuated vaccine strain. Proinflammatory cytokines IFN-γ, IL-2, and 
IL-9 were significantly induced in mice boosted with SopB5-GVNPs, consistent with a robust Th1 response. After challenge with 
virulent S. enterica serovar Typhimurium 14028, bacterial burden was found to be diminished in spleen of mice boosted with 
SopB4-GVNPs and absent or significantly diminished in liver, mesenteric lymph node, and spleen of mice boosted with SopB5-
GVNPs, indicating that the C-terminal portions of SopB displayed on GVNPs elicit a protective response to Salmonella infection 
in mice. SopB antigen-GVNPs were also found to be stable at elevated temperatures for extended periods without refrigeration. 
The results show that bioengineered GVNPs are likely to represent a valuable platform for antigen delivery and development of 
improved vaccines against Salmonella and other diseases. 
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1. Introduction 
1.1. Salmonella diseases 
Salmonella enterica, a Gram-negative intracellular pathogenic bacterium, infects humans and many warm blooded 
animals. Salmonellosis remains a serious problem in most developing countries and outbreaks are regularly seen in 
developed and industrialized countries1-4. Typhoid fever is caused by S. Typhi or S. Paratyphi, with global incidence 
of 21.7 million cases of Typhi and an additional 5.4 million Paratyphi cases resulting in 217,000 deaths per year5. 
Treatment is becoming more challenging due to increased prevalence of antibiotic resistance6-8. While two licensed 
vaccines for typhoid fever are commercially available, they have limited protection and/or may not be administered 
to immunocompromised people or children and infants. As a result, there is a critical need to develop more effective 
Salmonella vaccine candidates, which would also be safe and easily scalable, and inexpensive to produce and 
deliver. A versatile, particulate antigen delivery system, gas vesicle nanoparticles (GVNPs), which can be 
bioengineered to express multiple Salmonella antigens is likely to offer significant advantages over currently 
available vaccines, due to reduced risk and improved effectiveness.  
 
1.2. Salmonella pathogenesis and vaccine status 
 
Salmonella enterica includes 2,500 serovars infecting humans, and several are of public health importance, 
including S. Typhi and S. Paratyphi, the causative agents of typhoid and paratyphoid fever2,9,10. Transmission occurs 
through the fecal-oral route, upon ingestion of contaminated water and food. Occurrence of the disease may be 
confirmed by isolation of the pathogen, detection of antibodies against Salmonella specific O (somatic) and H 
(flagellar) antigens in the serum, or most sensitively, PCR based methods which utilize specific primers designed 
against unique regions of their genomes8. Treatment however is becoming more challenging, due to increased 
prevalence of multiple drug resistant (MDR) strains6,7. The need for improved vaccines against typhoid fever has 
been amply underscored by recent WHO reports3,4. 
 
Development of effective vaccines against Salmonella diseases is challenging due to its complex lifecycle11. The 
facultative intracellular pathogen enters the host by crossing intestinal epithelial cells via Peyer’s patches and 
infecting monocytes, macrophages, and dendritic cells. The bacteria can then travel to the mesenteric lymph nodes 
(MLN), spleen, and liver via circulating phagocytes. The host defense mechanisms for clearing Salmonella involve 
stimulation of both the adaptive and innate immune systems12. The importance of Th1 cells was shown by depletion 
of IFN-J and CD4+ T cells have been shown to play a significant role in immunity induced by Salmonella 
flagellin15,16 and live attenuated Salmonella17. B cell depletion studies and immunization studies in Ig-deficient mice 
also indicate the importance of B cells for immunity against Salmonella18,19. Salmonella during its intracellular life 
in macrophages also induces a modification of lipopolysaccharides (LPS) recognized by TLR-4 and triggers a 
downstream signaling cascade to evoke host immune response. As a result of these complexities, it is clear that 
potent antigens as well as adjuvants are important in potentiating the immune response and modulating its quality. 
 
Early efforts to develop an effective vaccine against Salmonella began with whole, killed cells, which were shown 
to be moderately effective in field trials in the 1960s, but most countries have eliminated its use due to undesired 
side effects. Currently, two licensed commercial vaccines for typhoid fever, a subunit (Vi polysaccharide or Vi PS) 
and a live attenuated S. Typhi strain (Ty21a), are commercially available. However, the use of these vaccines is 
limited because of the short period of protection and lack of effectiveness in small children. The Vi PS vaccine 
given in a single dose provides protection for only 3 years, while the live oral vaccine Ty21a requires 3-4 doses for 
~7 years of protection. For Ty21a, the limitations include requirement of large numbers (109) of bacteria, its 
inactivation by stomach acidity, and limited period of protection. The Ty21a vaccine cannot be used by children 
under the age of 6 or immunocompromised individuals. The Vi PS does not induce a switched antibody response, 
requires frequent boosts, and also cannot be used to immunize infants under the age of 2. Additionally, there are no 
licensed vaccines against S. Paratyphi A or B.  
 
In order to address these limitations, we are developing an improved vaccine utilizing an innovative new adjuvant 
and antigen delivery system, gas vesicle nanoparticles (GVNPs)20,21. To select antigens for display, we conducted 
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Figure 1. Halobacterium sp. GVNPs. A. Purified by flotation; B. 
Observed as phase bright particles in light microscopy; C. Observed 
in electron microscope after negative staining20,23. 
bioinformatic analysis of secreted proteins of S. enterica serovar Typhimurium (S. typhimurium) and S. enterica 
serovar Typhi (S. typhi) in pathogenicity islands 1 and 2 to map MHC-I and MHC-II binding epitopes22. In initial 
studies, a secreted inositol phosphate phosphatase protein, SopB, was selected and displayed on GVNPs and elicited 
strong immunogenic responses, partially protecting animals challenged with virulent Salmonella23. 
1.3. Gas Vesicle Nanoparticles 
GVNPs offer a novel antigen delivery system with powerful adjuvanting properties that is likely to enhance the 
prospect of an improved Salmonella vaccine. The ability of GVNPs to deliver multiple antigens, and their stability, 
scalability and safety, represent significant innovations. These nanoparticles are buoyant, hollow, and lemon-shaped, 
and are naturally produced by salt-loving nonpathogenic microorganisms, called Haloarchaea, a group of the 
Archaea (3rd Domain of life) lacking lipopolysaccharides (LPS)24. A large gene cluster (gvp) coding these 
nanoparticles has been cloned and extensively characterized20,25-29. In previous work, antigenic proteins and peptides 
have been successfully displayed on GVNPs, and in all cases, they were highly immunogenic in mice, with no toxic 
effects at either at the site of administration or systemically23,30-33. GVNPs are taken up by macrophages and 
processed slowly, producing strong long-lived humoral and cellular immune responses. GVNPs act as adjuvants 
when administered intraperitoneally or subcutaneously in mice. The nanoparticles are easily purified as a result of 
their buoyancy after simple osmotic cell lysis. GVNPs have a very long shelf life at room temperatures due to their 
high material strength, and the cost of producing large quantities of bioengineered GVNPs is low. As a result, 
GVNPs have great potential as an inexpensive, safe, and innovative antigen delivery and vaccine development 
system. 
 
1.3.1. Properties of gas vesicle nanoparticles (GVNPs) 
 
Our approach employs GVNPs (Figure 1) from the salt-loving haloarchaeal microbe, Halobacterium sp. NRC-
121,28,34-36. GVNPs consist of a thin (20 Å) lipid-free, rigid protein membrane surrounding a gas-filled space37. 
GVNPs are lemon-shaped, about 300 nm long, and 
150 nm in diameter, and grow from small bicones to 
progressively larger structures. During this process, 
water is excluded by hydrophobicity at the inner 
surface of the membrane, while ambient gases 
accumulate through passive diffusion. GVNPs are 
released by osmotic cell lysis with hypotonic 
conditions and may be easily purified in large 
quantities by centrifugally accelerated flotation (Figure 
1)25. Extreme resistance of the GVNP membrane to 
solubilization by detergents and chaotropic agents has 
precluded detailed biochemical studies38. However, 
GVNPs have been extensively studied using genetic, 
proteomic and immunological approaches20,26,29,39-43. 
 
GVNPs have ideal properties as an adjuvant and antigen delivery system. They are extremely stable, yet non-toxic, 
and genetically engineerable for displaying proteins on their surface. Their protein composition has been studied in 
considerable detail using immunological probes and proteomic studies, which has shown that at least 7 proteins are 
present in the nanoparticles25,29,44-46. Genetic analysis has shown the involvement of 14 genes 
(gvpMLKJIHGFEDACNO) in GVNP biosynthesis21,27,36. Within the gvp gene cluster is the gvpC gene, which codes 
for the second-most abundant GVNP protein, displayed on the external surface of the nanoparticles. GvpC protein 
was observed in GVNPs by immunoblotting26 and gvpC mutants produced smaller GVNPs than wild-type20,27, 
indicating their function in strengthening the nanoparticles44,47 (our unpublished data). The NRC-1 GvpC protein 
contains a novel protein motif which is repeated 8 times (Figure 2), and it is likely that GvpC functions in binding to 
the major GvpA protein on the GVNP surface. Insertions of sequences coding ≥ 250 amino acids after the 6th GvpC 
repeat are tolerated without disrupting GVNP formation, providing a site for insertion of foreign antigenic 
sequences20,23,30-31. 
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Figure 3. (Upper panel) Salmonella SopB4 and B5-gvpC3 
fusion genes used for expression in Halobacterium. Western 
blotting detection of GvpC-SopB fusion proteins in GVNPs 
purified from wild-type NRC-1, SD109 (pSDsopB4), and 
SD109 (pSDsopB5) probed with antisera against SopB4 
(lower left panel) and SopB5 (lower right panel)23. 
Figure 2. The amino acid sequence of GvpC of Halobacterium sp. NRC-1 is 
shown with conserved residues (vertical bars) in the eight imperfect repeats. 
The GvpC segments used in this study are labelled C1, C2, C3 and C4 at the 
C-terminal end. The position of the κ site is labelled ‘κ’23. 
1.3.2. Bioengineered GVNPs as adjuvant and antigen delivery system 
 
GVNPs have advantages over live-attenuated vectors, due to reduced risk, and over conventional purified antigens, 
through enhanced protection48. Bioengineered GVNPs function as both adjuvant and delivery system, via 
presentation of antigens to the antigen 
presentation cells (APCs), and as 
immunopotentiators, increasing 
immunogenicity without adverse 
reactogenicity49. Known desirable qualities of 
particulate delivery systems, including the 
size, charge, hydrophobicity, and shape of 
particles, all favor GVNPs as an effective 
adjuvant50. The GVNPs are in the nanometer 
range (virus-sized), found to be ideal for 
cytotoxic T cell responses, including cross-
presentation of vaccine antigens. GVNPs have 
surface charges and hydrophobic properties 
which have been shown to increase 
adjuvanting properties due to better interactions with APCs and phagocytes. The non-spherical lemon-shape of 
GVNPs is also expected to result in more effective adjuvanting properties. The ability to control the structure and 
accessibility of the GVNP surface are also desirable properties for antigen display and vaccine development. 
 
The effectiveness of GVNPs as an adjuvant and antigen delivery system is also favored by their ability for 
administration via multiple routes. While traditional human vaccines have been administered by needle injection, 
parenteral delivery mainly induces circulating antibodies49,50. The ability to administer GVNPs via alternate 
administration routes, particularly mucosal administration, may reduce cost and improve compliance, while 
simultaneously increasing mucosal immunity without reducing systemic immunity. In the case of preventing illness 
resulting from the Salmonella pathogen, oral administration employing GVNPs seems highly desirable from both 
the convenience and effectiveness standpoints.  
2. Experimental approach and findings 
2.1. Salmonella antigen display on GVNPs and immunological testing 
The Salmonella enterica antigen SopB was selected for 
GVNP-display and testing8,20,23,51. For this work, SopB4 
and B5 (amino acids 300-400 and 395-561, respectively) 
were synthesized as codon optimized-gene fragments, 
using information from the fully sequenced Halobacterium 
sp. NRC-1 genome to replace rare codons with frequently 
used codons52. The synthetic fragments were cloned in the 
expression plasmid (pSD104) into a unique AfeI site in the 
plasmid gvpC gene25,30. The resulting plasmids, pSDsopB4 
and pSDsopB5, contained the respective SopB coding 
regions inserted in-frame into the gvpC gene (Figure 3). 
These plasmids were transformed into Halobacterium 
strain SD109, which has the entire gvp gene cluster 
deleted53. 
 
To determine if the gvpC-sopB4 and gvpC-sopB5 fusion genes were expressed in Halobacterium, transformed 
strains were grown under mevinolin selection on agar plates, and colonies examined for GVNP production. 
Transformants containing pSDsopB4 or pSDsopB5 were lysed by exposure to hypotonic conditions, and GVNPs 
20   P. DasSarma et al. /  Procedia in Vaccinology  9 ( 2015 )  16 – 23 
Figure 4. Effectiveness of Salmonella SopB4 and B5-GVNPs for immunogenicity and 
protection in a mouse model. A. Serum IFN-J levels in pre- (dark gray) and post- (light gray) 
immunized animals; B. Bacterial load in spleen of GVNP-immunized and pathogen 
challenged animals, and C. Survival after pathogen challenge (PBS-solid line, NRC-1 
GVNPs-dotted line and SopB5-GVNPs-dashed line)23. 
Figure 5. Western blots of cell lysates (lane 2: Halobacterium sp. 
NRC-1, lanes 3-10: Halobacterium sp. SD109 (SopB4). Top: A 
culture at room temperature over time, Bottom: Lysates exposed to 
50oC over time; Lane 1: Molecular weight marker, 2: 8 months, 3: 8 
months, 4: 4 months, 5: 7 days, 6: 6h, 7: 12h, 8: 24h, 9: 72h, 10: 120h.  
were isolated by centrifugally accelerated flotation. The nanoparticle proteins were fractionated by SDS-PAGE and 
antigenic proteins were identified by Western blotting analysis using rabbit polyclonal antisera prepared against 
synthetic peptides corresponding to SopB4 and B5 (Figure 3) or GvpC8,23,29. Proteins of expected sizes were 
observed in the Western blots of purified GVNPs from the Halobacterium expression strains, SD109 (pSDsopB4) 
and SD109 (pSDsopB5), but were absent in GVNPs from NRC-1, as expected, confirming production of the fusion 
proteins and their presence on the GVNPs. 
 
To determine the effect of 
Salmonella SopB4 and B5 antigens 
displayed on GVNPs, we 
immunized mice intraperitoneally 
(i.p.) with 103 colony forming units 
(cfu) of the S. Typhimurium 
attenuated strain followed by two 
boosts with 100 Pg each of SopB4, 
B5, or wild-type NRC-1 GVNPs 
respectively, 1 and 2 weeks post 
immunization. Cytokine responses 
were determined for each cohort of 
mice, and the most notable changes 
were found for mice immunized 
with SopB5-GVNPs. Serum levels 
of IFN-J GM-CSF, and IL-2, all of which are Th1 cytokines, were found to be significantly increased in post-
SopB5-GVNP-immunization sera compared to pre-immunization sera, indicating that the Th1 pathway involved in 
response to intracellular bacterial pathogens is induced by these GVNPs23 (Figure 4A).  
 
Following immunizations and boosting, mice were challenged orally with 107 cfu of wild-type Salmonella, and 
the MLN, liver, and spleen were isolated one week post-challenge. Bacterial loads were determined for each organ 
by plating dilutions and counting cfu. In each of the three organs, bacterial cfu were lower by at least two orders of 
magnitude for mice immunized with SopB5-GVNP23 (Figure 4B). Bacterial load in the spleen was also significantly 
reduced in SopB4-GVNP immunized mice. CD4+ T-cells were also found to be elevated by 2-4-fold in the spleen of 
mice immunized with SopB5-GVNPs compared to wild-type23. Further challenge experiments were conducted to 
determine protection and mice immunized with SopB5-GVNP survived 3-5 days longer than those immunized with 
wild-type NRC-1 (Figure 4C). 
 
2.2. Stability of GVNPs in Salmonella vaccine 
producing strains 
Halobacterium strains containing SopB-GVNPs 
were tested over several months for stability of the 
GvpC-SopB proteins using Western blotting assays. 
The recombinant GVNPs were found to be stable 
over several months at room temperature, as well as 
when exposed to high temperatures of 50oC, with 
little to no degradation of the Salmonella antigen 
displayed on the nanoparticles23 (Figure 5). Thus, our 
results clearly showed that the GVNP-antigen 
display system is shelf-stable without the need for 
refrigeration, even under tropical summer conditions. 
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Figure 7. Luciferase activity in purified GVNPs from Halobacterium 
sp. NRC-1∆ura3∆gvpC and Halobacterium sp. NRC-1 strains 
containing gvpC and luciferase expression plasmids. Percent luciferase 
activity, chemiluminescence activity detected in gas vesicles 
compared to total activity observed in cell lysates, is plotted on 
vertical axis for pDRK-C-L plasmid series. Values plotted are the 
average of triplicate experiments, and standard deviation is shown 
with error bars. A: pDRK-C1-L, B: pDRK-C2-L, C: pDRK-C3-L, D: 
pDRK-C4-L in either Halobacterium sp. NRC-1Δura3ΔgvpC (blue), 
or in wild-type Halobacterium sp. NRC-1 (pink) strain20. 
Figure 6. The upper map (pARK-C series) displays the KpnI-BamHI 
region of the pARK-C series plasmids, with the cspD2 promoter 
labelled Pcs, His-tag shown as red box, and gvpC gene (with C1, C2, 
C3, and C4 regions marked as in Figure 2) shown as blue arrow. The 
four lower maps (labelled pDRK-C1-L to C4-L) show the KpnI-
BamHI regions of pDRK-C-L plasmid series containing the gvpA 
promoter (labelled Pgv), His-tag (red box), C1, C2, C3, and C4 regions 
of gvpC (blue boxes), and codon optimized Gaussia princeps 
luciferase gene (yellow arrow). The corresponding sites of KpnI, NdeI, 
and BamHI cleavage are indicated, while the AfeI sites at the GvpC-
luciferase gene boundaries are not shown20. 
2.3. Improvement of the GVNP bioengineering 
system 
The genetic system used for bioengineering of 
SopB-GVNPs employed a relatively large plasmid, 
pSD104, containing the entire gvp gene28. In order to 
facilitate future bioengineering of nanoparticles, we 
constructed a series of smaller, more versatile 
plasmid expression vectors containing gvpC, as well 
as a gvpC deletion host strain20 (Figure 6). The 
Halobacterium sp. NRC-1'ura3'gvpC deletion 
strain, constructed using the ura3-based gene 
deletion method54, showed a partially gas vesicle-
deficient phenotype with small, mainly lemon-
shaped gas vesicles. We next constructed a gvpC 
expression vector series using pARK, an expression 
plasmid with the cold-inducible cspD2 promoter, and 
pDRK, an expression plasmid incorporating the 
higher-level gvpA promoter55,56. A series of PCR 
amplified gvpC gene fragments (C-series) were then inserted into the expression plasmids to test their ability to bind 
to GVNPs and complement nanoparticle production. The plasmids were transformed into the 'gvpC deletion strain 
and the results showed correlation between 
progressively longer gvpC fragments and larger 
size GVNPs20. 
 
Next, a codon-optimized synthetic gene coding 
luciferase from the marine copepod Gaussia 
princeps was fused to the gvpC gene fragments on 
the expression plasmid and resulted in production 
of the chemiluminescence protein on GVNPs20 
(Figure 7). When inserted together with a wild-type 
gvpC gene, we obtained GVNPs displaying both of 
the GvpC and GvpC-luciferase fusion proteins. 
This finding confirmed that multiple GvpC protein 
types may be expressed simultaneously on the 
surface of GVNPs, providing the capability to 
express multiple antigenic proteins and delivering 
multivalent GVNP vaccines in a single strain. This 
system also opens the potential for expression of 
other therapeutic proteins on GVNPs for 
applications to drug delivery.  
3. Conclusion 
Salmonella pathogens remain important causes of morbidity and mortality due to the lack of an effective, long-
lasting vaccine. Novel gas vesicle nanoparticles (GVNPs) produced by extremophilic Halobacterium sp. NRC-1 are 
being used to develop an improved vaccine against Salmonella pathogens that is both inexpensive and effective57. 
When administered to animals, GVNPs have previously been shown to produce strong long-lived humoral and 
cellular immune responses against surface-displayed antigens. In this study, a secreted protein conserved in 
Salmonella enterica pathogens, SopB, was displayed by genetic fusion to GvpC, a GVNP surface proteins, and the 
bioengineered SopB-GVNPs were found to be highly immunogenic in mice. Our results showed that animals 
boosted with SopB-GVNPs stimulated production of IgGs, proinflammatory cytokines, and CD4+ T cells, and 
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resulted in reduced bacterial load in key organs. Additionally, the vaccine-producing strains were found to be shelf-
stable over months when stored at room temperature and at elevated temperatures. We also developed an improved 
GVNP expression host and plasmid series and demonstrated its potential by displaying the Gaussia princeps 
luciferase reporter. This work opens the possibility of delivery of therapeutic proteins displayed on GVNPs. 
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